Please login to the form below

Not currently logged in

Roche files patent lawsuit against Teva for osteoporosis drug

Roche files a lawsuit against generic manufacturer Teva over an alleged patent violation on its osteoporosis treatment, Boniva

Swiss pharmaceutical company Roche has filed a lawsuit against Israel-headquartered generic manufacturer Teva over an alleged patent violation on its osteoporosis treatment Boniva (ibandronate).

A Roche spokesperson said the lawsuit was instituted to prevent Teva from marketing a generic version of Boniva 150 mg tablets. The basic patent runs until 2012, with further patents protecting the drug until 2023.

Boniva recorded sales of CHF 374m (USD 315.7m) in H1 FY07, according to Roche.

30th September 2008


Featured jobs

Subscribe to our email news alerts


Add my company

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...